E7386

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Food Effect in Healthy Participants

Conditions

Food Effect in Healthy Participants

Trial Timeline

Jun 7, 2019 → Oct 29, 2019

NCT ID

NCT03996226

About E7386

E7386 is a phase 1 stage product being developed by Eisai for Food Effect in Healthy Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT03996226. Target conditions include Food Effect in Healthy Participants.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04840927	Phase 1	Withdrawn	Apr 9, 2021	May 17, 2023	Healthy Volunteers
NCT03996226	Phase 1	Completed	Jun 7, 2019	Oct 29, 2019	Food Effect in Healthy Participants
NCT03833700	Phase 1	Active	Mar 5, 2019	Mar 31, 2027	Solid Neoplasms
NCT03264664	Phase 1	Active	Jul 27, 2017	Mar 31, 2027	Advanced Neoplasms

Competing Products

17 competing products in Food Effect in Healthy Participants

See all competitors

Product	Company	Stage	Hype Score
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C	Daiichi Sankyo	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
Acalabrutinib	AstraZeneca	Phase 2	52
esomeprazole/ASA Fixed Dose Combination (FDC)	AstraZeneca	Phase 1	33
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	77
Omalizumab	Novartis	Approved	85
Omalizumab Injection	Roche	Approved	85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	22
linvoseltamab + dupilumab	Regeneron Pharmaceuticals	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Phase 2	51
Sativex + Sativex + Sativex + Sativex	Jazz Pharmaceuticals	Phase 1	30
fruquintinib	HUTCHMED	Phase 1	28
Volitinib	HUTCHMED	Phase 1	28
Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin Placebo	DBV Technologies	Phase 1/2	36
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + Omeprazole	Ardelyx	Phase 1	28
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3	Allergy Therapeutics	Phase 1	28

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved